Rheumatoid Arthritis

A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)

Trial Status	Trial Runs In	Trial Identifier
Completed	0 Countries	NCT02797769 GA30048

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This retrospective cohort study will analyze data from multiple large U.S. health insurance claims databases to compare use of tocilizumab to other biologic disease-modifying antirheumatic drugs (DMARDs) in real world patients with RA. Using the date of dispensing as the index date, the analysis will compute the time to first event for several cardiovascular outcomes.

Hoffmann-La Roche Sponsor	N/A Phase
NCT02797769 GA30048 Trial Identifiers	
Eligibility Criteria:	

Gender

Age >=18 Years Healthy Volunteers